The venture capital landscape for biotechnology often follows a predictable geography, yet the launch of Tortugas Neuroscience suggests a more globalized strategy for addressing complex neurological disorders. Backed by a $106 million Series A from Cure Ventures, The Column Group, and AN Ventures, the startup is positioning itself as a conduit for promising molecules developed in Asia that have yet to reach the American clinical pipeline.
Tortugas is centering its initial efforts on four distinct assets. Two, licensed from China’s Jiangsu Hansoh Pharmaceutical Group, target schizophrenia and tinnitus—a move that highlights the growing sophistication of the Chinese biotech sector beyond its recent focus on oncology and metabolic health. The other two, sourced from the Japanese pharmaceutical giant Eisai, are intended to treat focal epilepsy and encephalopathies.
By acquiring these assets for mid-stage clinical trials in the United States, Tortugas is betting on a decentralized model of drug discovery. Rather than building a pipeline from scratch, the company is acting as a specialized architect, refining existing science to navigate the notoriously difficult regulatory and clinical hurdles of central nervous system disorders.
With reporting from STAT News.
Source · STAT News (Biotech)
